[The role of transmural permeability disorders in the pathomechanism of arteriosclerosis. II. Model experiments].
D000818:Animals; D001013:Aorta, Thoracic / Q000648:ultrastructure; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology* / Q000473:pathology; D002199:Capillary Permeability; D002463:Cell Membrane Permeability; D003327:Coronary Disease / Q000097:blood / Q000209:etiology* / Q000473:pathology; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D004338:Drug Combinations / Q000008:administration & dosage; D004727:Endothelium / Q000648:ultrastructure; D006937:Hypercholesterolemia / Q000150:complications* / Q000473:pathology; D006974:Hypertension, Malignant / Q000150:complications / Q000473:pathology; D000860:Hypoxia / Q000150:complications / Q000473:pathology; D008209:Lymphedema / Q000150:complications / Q000473:pathology; D008854:Microscopy, Electron; D010743:Phospholipids / Q000008:administration & dosage; D051381:Rats; D013012:Sorbitol / Q000008:administration & dosage; D013897:Thoracic Duct / Q000473:pathology
D004338:Drug Combinations; D010743:Phospholipids; C008288:Lipofundin; D013012:Sorbitol
A transzmurális permeabilitás zavarának szerepe az arteriosclerosis patomechanizmusában II. Modellkisérletek.